Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro

Alzheimer's disease (AD) is the consequence of neuronal death and brain atrophy associated with the aggregation of protein tau into fibrils. Thus disaggregation of tau fibrils could be a therapeutic approach to AD. The small molecule EGCG, abundant in green tea, has long been known to disaggregate tau and other amyloid fibrils, but EGCG has poor drug-like properties, failing to fully penetrate the brain. Here we have cryogenically trapped an intermediate of brain-extracted tau fibrils on the kinetic pathway to EGCG-induced disaggregation and have determined its cryoEM structure. The structure reveals that EGCG molecules stack in polar clefts between the paired helical protofilaments that pathologically define AD. Treating the EGCG binding position as a pharmacophore, we computationally screened thousands of drug-like compounds for compatibility for the pharmacophore, discovering several that experimentally disaggregate brain-derived tau fibrils in vitro. This work suggests the potential of structure-based, small-molecule drug discovery for amyloid diseases. Evidence suggests that fibrous aggregates of protein tau may be the proximal cause of Alzheimer's disease. Here, using atomic structures of tau fibrils from brains of people with Alzheimer's disease, the authors have found small-molecule drug leads that disaggregate tau fibrils in vitro.

Automated summary

The study finds that EGCG in green tea can disaggregate Tau fibrils, but its poor drug-like properties limit its effectiveness in treating Alzheimer's disease. By using cryoEM structure, the researchers have discovered other compounds that can disaggregate Tau fibrils and suggest the potential of structure-based, small-molecule drug discovery for amyloid diseases.